Pfizer Shares Slip After Q1 Call Highlights Pipeline, Cost Cuts and Seagen Integration

Pfizer Inc. (PFE) traded at $25.78 as of May 15, 2026, down from $26.30 before its first-quarter earnings call, after management cited growth from recently launched and acquired products while investors focused on pipeline execution, cost controls and vaccine demand. CEO Albert Bourla said revenue from new products and acquisitions rose 22%, supported by the integration of Seagen and demand for migraine drug Nurtec. Management also cited legal settlements that improved visibility on post-2028 growth and cash flow. CFO David Denton said cost management and targeted research-and-development spending contributed to the quarter’s performance. Key investor questions centered on pivotal obesity and oncology studies, capital allocation after improved cash flow visibility, vaccine uptake trends and the pace of specialty drug launches.